Mon, Mar 2, 2015, 2:56 AM EST - U.S. Markets open in 6 hrs 34 mins


% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, Inc. Message Board

  • blue_aka_chip blue_aka_chip Jun 19, 2001 3:29 PM Flag

    Awesome Glioblastoma News!!

    Oncolytics Biotech Inc. Announces Results of REOLYSIN(R)
    Treatment of Brain Cancer (Gliomas) in Animal Models
    CALGARY, ALBERTA--Oncolytics Biotech Inc. (TSE:ONC, or
    "Oncolytics") reported today that Dr. Peter Forsyth and his
    research group with the Alberta Cancer Board and the University of
    Calgary are publishing the results of their work with REOLYSIN(R)
    for the treatment of human malignant gliomas (brain cancer) in
    animal models. The results will be published in the June 20, 2001
    issue of the Journal of the National Cancer Institute. Oncolytics
    holds the Patent rights to the pharmaceutical use of REOLYSIN(R)
    for the treatment of cancer.

    Dr. Forsyth and his colleagues were able to demonstrate that nude
    mice with intracerebral (in the brain) gliomas treated with a
    single injection of REOLYSIN(R) administered intratumourally
    survived significantly longer than untreated animals in the
    control group (p<0.0001). The median survival times of two
    different glioma tumour types, U251N and U87lacZ, in untreated
    animals was 42 and 48 days respectively. None of the untreated
    animals survived through the experiment. When the experiments were
    terminated after 90 days, 67% and 82%, respectively, of the live
    virus treated animals were still alive. Live virus treated animals
    in both cases appeared healthy and gained weight, while untreated
    animals lost weight. Complete tumour regression was found in 20
    of the 23 animals treated with live virus.

    The research group also examined the ability of REOLYSIN(R) to
    infect and kill cancer cells from established glioma cell lines
    and brain tumor surgical specimens. Widespread cell killing was
    seen in 79% (19/24) of established glioma cell lines tested.
    Sixteen brain tumor surgical specimens were also tested, including
    nine gliomas. REOLYSIN(R) infected and killed all nine of the
    primary glioma cultures.

    "The complete regression of the tumour mass in most of the live
    virus treated animals is very encouraging. The life span
    extension and weight gains found in these animals after
    REOLYSIN(R) treatment is nothing short of remarkable," said Dr.
    Brad Thompson, President and CEO of Oncolytics. "Oncolytics has
    completed the initial part of formal toxicology studies examining
    the effects of injecting REOLYSIN(R) into the brains of test
    animals and have found no side effects of note. We expect the
    combination of these results with those of Dr. Forsyth will lead
    to a clinical study examining the use of REOLYSIN(R) to treat
    malignant gliomas later this year."

    Oncolytics is a Calgary-based biotechnology company whose focus is
    the development of the mammalian reovirus based product known as
    REOLYSIN(R) as a potential cancer therapeutic. The mammalian
    reovirus infects and kills cancer cells with an activated Ras
    pathway. Ras is an important component of a pathway controlling
    normal growth and differentiation of a cell, and when activated,
    may account for a large proportion of all mammalian tumours.
    Researchers believe that targeting this pathway could have broad
    potential in the treatment of many cancers. Oncolytics researchers
    demonstrated that reovirus was selectively able to kill cancer
    cells with this particular activation and successfully
    demonstrated that the virus could kill human cancer cells in vitro
    derived from breast, prostate, pancreatic and brain tumors, as
    well as being able to treat tumours successfully in a number of
    animal models. Oncolytics initiated its Phase I clinical trial on
    REOLYSIN(R) in June, 2000 and in May, 2001 filed an
    investigational new drug submission for a Phase II clinical trial
    on REOLYSIN(R) for the treatment of Stage T2A prostate cancers. In
    November 2000, the Company entered into a worldwide licensing
    agreement with Pfizer Inc. fo

    SortNewest  |  Oldest  |  Most Replied Expand all replies
124.700.0000(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.